Roxadustat Trials

Our most advanced product candidate, roxadustat, is progressing through a global Phase 3 clinical development program for the treatment of anemia in chronic kidney disease, and will be entering Phase 3 development in the U.S. and Phase 2/3 development in China this year for treatment of anemia associated with myelodysplastic syndromes. The goal of these clinical studies is to evaluate the safety and efficacy of the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor therapy for the treatment of anemia.


  • FG-4592-064, Phase 3, Anemia in dialysis-dependent CKD patients
    > Currently enrolling
  • FG-4592-063, Phase 3, Anemia in incident dialysis-dependent CKD patients
    > Currently enrolling
  • FG-4592-060, Phase 3, Anemia in non-dialysis-dependent CKD patients
    > Currently enrolling
  • FG-4592-082, Phase 3, Anemia in MDS patients
    > Not yet recruiting